MDxHealth articles
Background: Prostate cancer (PCa) diagnosis is challenging because efforts for effective, timely treatment of men with significant cancer typically result in over-diagnosis and repeat biopsies. The presence or absence of epigenetic aberrations, more specifically DNA-methylation of GSTP1, RASSF1, and APC in histopathologically negative prostate core biopsies has resulted in an increased negative predictive value (NPV) of ∼90% and thus could lead to
Objective: To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations.
Materials and methods: The study population consisted of 211 AA men from 7 urology centers across the United States; all of
BACKGROUND
Non-invasive techniques like urinary biomarkers and multiparametric Magnetic Resonance Imaging (mpMRI) show great promise for the detection of clinically significant prostate cancer (PCa), leading to a reduction of over-diagnosis and over-treatment. Apart from yet to be established diagnostic accuracy is the systematic use of mpMRI challenging due to the high cost of setting up, staffing and maintaining a mpMRI unit. Upfront risk strati
Purpose: SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with traditional risk factors to individualize risk prediction for clinically significant prostate cancer. In this study we sought to characterize the effectiveness of SelectMDx in a population of American men with elevated prostate specific antigen.
Materials and methods: We developed a Markov decision analytical model
Organizations